Peter Strong
Gründer bei Pulmocide Ltd.
Profil
Peter Strong was the founder of RespiVert Ltd.
(founded in 2006) where he held the title of Head-Drug Discovery from 2006 to 2011.
He is also the founder of Pulmocide Ltd.
(founded in 2007) where he currently holds the title of Director & Chief Scientific Officer.
Prior to his founding positions, Dr. Strong worked as a Principal at GSK Plc from 2004 to 2004 and as a Senior Biochemist at Glaxo Group Ltd.
Dr. Strong obtained a doctorate degree from the University of Leeds and an undergraduate degree from The University of York.
Aktive Positionen von Peter Strong
| Unternehmen | Position | Beginn |
|---|---|---|
Pulmocide Ltd.
 Pulmocide Ltd. Pharmaceuticals: MajorHealth Technology Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom. | Gründer | 23.03.2007 |
Ehemalige bekannte Positionen von Peter Strong
| Unternehmen | Position | Ende |
|---|---|---|
| GSK PLC | Corporate Officer/Principal | 01.01.2004 |
Glaxo Group Ltd.
 Glaxo Group Ltd. Pharmaceuticals: MajorHealth Technology Founded in 1935, Glaxo Group Ltd. is a subsidiary of GSK Plc. The company is based in Middlesex, UK. At GSK, we unite science, technology and talent to get ahead of disease together. | Corporate Officer/Principal | - |
RespiVert Ltd.
 RespiVert Ltd. Medical DistributorsDistribution Services RespiVert Ltd. operates as a small molecule drug discovery company. The firm develops small-molecule inhaled therapies for the treatment of chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. The company was founded by William Garth Rapeport, Peter Strong, Kazuhiro Ito, John Murray and Peter Barnes in 2007 and is headquartered in London, the United Kingdom. | Gründer | - |
Ausbildung von Peter Strong
| The University of York | Undergraduate Degree |
| University of Leeds | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| GSK PLC | Health Technology |
| Private Unternehmen | 3 |
|---|---|
RespiVert Ltd.
RespiVert Ltd. Medical DistributorsDistribution Services RespiVert Ltd. operates as a small molecule drug discovery company. The firm develops small-molecule inhaled therapies for the treatment of chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. The company was founded by William Garth Rapeport, Peter Strong, Kazuhiro Ito, John Murray and Peter Barnes in 2007 and is headquartered in London, the United Kingdom. | Distribution Services |
Pulmocide Ltd.
Pulmocide Ltd. Pharmaceuticals: MajorHealth Technology Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom. | Health Technology |
Glaxo Group Ltd.
Glaxo Group Ltd. Pharmaceuticals: MajorHealth Technology Founded in 1935, Glaxo Group Ltd. is a subsidiary of GSK Plc. The company is based in Middlesex, UK. At GSK, we unite science, technology and talent to get ahead of disease together. | Health Technology |
